What Volulyte Treats: Main Uses and Benefits

Volulyte (Hydroxyethyl Starch 130/0.4) is applied as a plasma volume substitute and is commonly used when supportive assistance is needed for symptoms related to systemic imbalance. It is considered relevant in contexts involving heightened systemic burden where short-term symptomatic assistance is appropriate.

Within the HES 130/0.4 product category, this medication is used to help with managing hypovolemia, a condition presenting with systemic or localized discomfort, in adults and children.

The medication is relevant for easing symptoms that cluster into patterns requiring supportive management, such as those associated with low blood pressure (hypotension) and symptoms that create noticeable physiological strain. This supportive relief helps ease the overall symptom load during periods of heightened discomfort.

It plays a role in managing symptoms related to systemic imbalance across conditions presenting with acute episodes, including those following trauma and major surgical procedures.

“Supportive relief helps patients cope more steadily with difficult episodes by easing distress related to symptoms that interfere with daily functioning.”

Quick Fact: Relief for Acute Volume Deficits

The primary benefit is supportive volume expansion, which assists with managing conditions associated with acute or episodic changes in clinical settings marked by acute or unstable symptom patterns. It may assist with maintaining functional stability by supporting blood pressure during episodes associated with acute changes.

Who Can and Cannot Use Volulyte?

Volulyte (Hydroxyethyl Starch 130/0.4) eligibility is defined by strict regulatory contraindications, primarily excluding patients with pre-existing critical conditions or volume instability. The medicine is approved for use in adult patients experiencing hypovolemia (low blood volume) due to acute blood loss.

Absolute Contraindications

Use is strictly prohibited for critically ill adult patients, including those with sepsis, due to documented risks of increased mortality and renal injury. Contraindications also apply to patients with:

• Fluid overload (hyperhydration), pulmonary edema, or congestive cardiac failure.
• Severe liver disease or pre-existing bleeding disorders.
• Renal failure (unrelated to hypovolemia) or those undergoing dialysis.
• Severe hypernatremia, hyperchloremia, or intracranial bleeding.

Population Restrictions

Population	Regulatory Status
Pediatrics (Children)	Not recommended due to limited long-term safety data.
Pregnancy	Use with caution, only if the benefit outweighs the potential risk to the fetus.
Renal Dysfunction	Use must be avoided in patients with pre-existing renal dysfunction and stopped at the first sign of kidney injury.

Interactions with Other Medicines and Products: Official Profile Summary

The official regulatory profile for Volulyte (Hydroxyethyl Starch 130/0.4) indicates that no formal interactions with other medicines or nutritional products are known to date according to government-approved prescribing information. The interaction profile is structured around one specific pharmacodynamic caution and a known interference with a laboratory test.

---

Documented Interaction Cautions

Pharmacodynamic Interaction

Volulyte is formulated as a balanced electrolyte solution containing sodium and potassium salts. For this reason, official labels recommend that consideration should be given to the concomitant administration of medicinal products that are known to cause retention of sodium or potassium in the body. This is a general caution related to the potential for additive effects on the body's fluid and electrolyte balance.

Drug-Laboratory Test Interference

Administration of hydroxyethyl starch may cause a rise in the level of the enzyme serum amylase. This elevation is a documented interference that can complicate the diagnosis of inflammation of the pancreas (pancreatitis). Regulatory sources explicitly state that this amylase elevation is not considered diagnostic of pancreatitis and is an expected effect of the medication itself. No timing-based rules or specific prohibitions against other medicines are documented due to interaction risk.

Volulyte functions as a plasma volume substitute primarily through its active component, Hydroxyethyl Starch (HES 130/0.4). The HES molecules, characterized by a mean molecular weight of 130,000, Da and a molar substitution of 0.4, are large non-ionic colloid particles. These large molecules primarily remain within the intravascular space following intravenous administration, as they are not readily filtered by the glomerulus.

Molecular and Systemic Consequences

This intravascular persistence exerts a significant osmotic pressure, drawing extracellular fluid from the interstitial space into the vascular compartment. This molecular action results in an expansion of the circulating blood volume. The duration and magnitude of the systemic volume expansion are directly correlated with the physicochemical properties of the HES, specifically its molecular weight and molar substitution, which dictate the rate of enzymatic degradation by plasma alpha-amylase. Smaller HES molecules are rapidly cleaved and subsequently excreted renally, while larger molecules remain for a prolonged duration, maintaining the volume expansion and inducing hemodilution of blood components.

Instruction Map: How to use Volulyte — Administration Guidelines

---

Administration Scope

Instruction	Detail
Route of administration	Intravenous infusion only.
Dosing schedule	Maximum daily dose is up to 50 mL/kg of body weight per day (equivalent to 3 g HES per kg); use is restricted to the 24-hour initial phase of volume replacement.
Timing in relation to meals (if applicable)	Not applicable, as administration is by intravenous infusion.
Preparation requirements (if applicable)	Must be visually checked for clarity and freedom from particles; the solution is for single use only, and any unused portion must be discarded.
Age-group administration rules	Adolescents (>12 years) share the adult maximum dose. Dosage in children (<12 years) must be adapted to individual needs, with reported clinical means ranging from 16 mL/kg to 36 mL/kg.
Missed-dose rules	Not applicable, as administration is based on acute, titrated needs under continuous clinical supervision.
Special procedural conditions	The initial 10 to 20 mL must be infused slowly. In cases of severe dehydration, a crystalloid solution should be administered first.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Intravenous (IV) infusion
Frequency pattern	As-needed (titrated); can be administered repetitively, but use is restricted to the initial phase of volume replacement.
Use-context constraints	Administration is time-constrained, often limited to 24 hours from the start of treatment, and guided by continuous monitoring.

---

Resulting Procedural Structure

Step sequence:

• Administer a crystalloid solution first if the patient is severely dehydrated.
• Initiate the infusion by administering the initial 10 to 20 mL slowly.
• Titrate the subsequent rate of infusion and total volume based on the patient’s hemodynamic status, while strictly adhering to the maximum daily dose.
• Discontinue the infusion when appropriate hemodynamic goals are achieved or at the limit of the treatment time constraint.

Connection to the overall use protocol: The use of Volulyte is a controlled, procedural intervention with distinct constraints on volume and time. The protocol mandates adherence to the Intravenous route, precise dosing limits, and an initial slow infusion rate to govern its proper administration. This framework dictates the technical conditions for its use, ensuring the administration pattern is consistent with recognized clinical standards.

Research evidence / Overview of studies for Volulyte

---

Evidence for Volume Replacement in Acute Blood Loss

Research was studied for Volulyte's use primarily in situations where patients need rapid replacement of circulating fluid volume due to acute blood loss, such as during major surgical procedures or following trauma. Studies conducted for this purpose are typically Randomized Controlled Trials (RCTs), where Volulyte is evaluated in comparison to other standard intravenous fluids, like simple salt solutions (crystalloids). These trials monitored adult patients and physical measurements of the circulatory system.

The primary aim of these studies was to monitor the solution's ability to achieve and maintain a stable hemodynamic status—meaning stable blood pressure and heart rate—in the short term. The data show patterns related to initial changes in volume status in the observed patient groups. Research also explored how the required volume of Volulyte compared to the volume of alternative fluids needed to achieve similar stability.

However, comparative evidence is lacking to establish whether Volulyte differs from alternative fluids for all patient-centered outcomes. The evidence highlights what is known about its short-term effects, but the necessity of this specific type of fluid remains uncertain for many outcomes when used in the currently approved populations.

---

Outcomes Studied in Major Clinical Trials

Beyond immediate volume replacement, major clinical research studies explored other important patient-relevant outcomes. Key areas of investigation included monitoring renal function, specifically looking for any change in the rate of Acute Kidney Injury (AKI) or the subsequent requirement for Renal Replacement Therapy (RRT) (a type of dialysis).

Research also explored coagulation parameters, with studies monitoring the patient’s ability to clot blood and the amount of blood products (transfusions) that patients required during the perioperative period. Furthermore, large trials were evaluated in the context of overall patient survival, often tracked at 90 days after treatment.

---

Research in Special Patient Populations

Studies have explored the use of Volulyte in specific high-risk groups, including critically ill patients with sepsis and severe trauma. As noted by regulators, the findings were mixed, and data show patterns related to certain outcomes (such as the need for RRT or mortality) was observed in some studies in these critically ill settings. Consequently, the research conducted in these high-risk groups informs the current regulatory restrictions, with the medicine not being indicated for these specific critically ill patients.

Key Studies & References

1. Volulyte 6% solution for infusion (Summary of Product Characteristics/Patient Information) – HPRA (reflecting EMA restrictions)
2. The Crystalloid versus Hydroxyethyl Starch Trial (CHEST): study protocol, design, and rationale for a blinded multicenter randomised controlled trial
3. Mortality after hydroxyethyl starch 130/0.4 infusion: an updated meta-analysis of randomized trials (Gattas et al., 2012)

Common questions about Volulyte (FAQ)

---

Q: Is Volulyte the same as normal saline or other IV fluids?

A: Official information indicates that Volulyte is classified as a colloid solution, a type of plasma volume substitute, because it contains large starch molecules. This differs from IV fluids known as crystalloid solutions (like normal saline). Official guidance indicates the product is for plasma volume replacement only when treatment with alternative crystalloid solutions alone is not considered sufficient to restore lost blood volume.

---

Q: Can Volulyte be given to pregnant or breastfeeding individuals?

A: Regarding pregnancy, official documents state that there are no clinical studies available. Therefore, its use is considered appropriate only when the healthcare provider determines the potential benefit outweighs the potential risk to the fetus. The safety of the product in breastfeeding women has not been formally investigated in studies and is not established.

---

Q: Are there warnings about Volulyte use in older adults (seniors)?

A: While there is no specific age limit given for older adults in official documents, caution and careful monitoring are generally emphasized for patients with underlying health issues. Official guidance includes the need for careful monitoring for patients with underlying health issues, such as heart or circulation problems. Adjusting the dose with care may be necessary, based on the physician’s assessment.

---

Q: Does Volulyte interact with common anticoagulant (blood thinning) medicines?

A: Official information notes that the use of the active substance, hydroxyethyl starch, can cause disturbances in blood clotting depending on the dosage administered. It is known to cause the dilution of blood components and is strictly contraindicated in severe pre-existing blood clotting disorders. The medical team is responsible for assessing all concurrent medications, including anticoagulants, during treatment.

---

Q: Can Volulyte change the results of routine lab work?

A: Yes, official safety information states that administration of the active substance can cause a rise in the level of the enzyme serum amylase in the blood. This change is an expected effect of the medicine and is not considered diagnostic of pancreatic inflammation, but it can interfere with the diagnosis of that condition.

---

Q: Does the use of Volulyte require blood tests before or after?

A: Official regulatory guidance mandates close monitoring during and after administration. This includes checking the patient’s ability of their blood to clot, bleeding time, and overall kidney function. Monitoring these functions, as required by regulatory guidance, involves assessing blood components and markers of organ function.

---

Q: Are there patient registries or follow-up studies for people who received Volulyte?

A: Government reviews have referenced the results of post-marketing surveillance and studies that track how the drug is used in clinical settings. The regulatory safety review processes have included follow-up on patient outcomes, such as the need for renal replacement therapy (dialysis) up to 90 days after administration.

---

Q: Does Volulyte cause changes in kidney function?

A: Official information requires the monitoring of renal function (kidney function) during and after Volulyte use. The medicine is contraindicated in patients who have pre-existing renal failure, and treatment must be stopped immediately at the first sign of any kidney impairment. Official guidance requires continuous monitoring of kidney function, with regulatory reviews having tracked outcomes up to 90 days following administration.

---

Q: How quickly does Volulyte start to work in the body?

A: The medicine is intended to provide rapid plasma volume expansion (increasing the fluid volume in your blood vessels), which begins immediately upon the start of the intravenous infusion. Studies in healthy subjects have reported this volume expansion effect lasting for a number of hours after a standard infusion.

---

Q: How long does the effect of Volulyte last after it's been administered?

A: Studies on the active substance, Hydroxyethyl Starch, indicate that the volume expansion effect can last for approximately four to six hours after a standard dose is infused in healthy subjects. The exact duration may vary depending on the patient and the administered dose.

---

Q: Are there any long-term side effects associated with Volulyte use?

A: Official documents have cited uncertainty with regard to long-term safety for this class of medicine. Due to concerns about safety, its use is restricted to only the initial 24-hour phase of fluid volume replacement. The lack of robust long-term safety data in certain populations is a factor that has influenced regulatory decisions to restrict its use.

---

Q: What are the most common patient-reported side effects of Volulyte?

A: According to official prescribing information, the most common reported adverse effect, occurring in up to 1 out of 10 patients, is pruritus (itching). Other commonly reported effects are related to the dilution of blood components that can occur with high dosages.

---

Q: Can Volulyte be used for children or pediatric patients?

A: The medicine is not recommended for use in children due to limited experience and the lack of robust data on its safety and effectiveness in this population. If used, the administration and dose are determined by the treating clinician based on the individual child's needs and status.

---

Q: What is the difference between Volulyte and similar volume expanders like Gelatin?

A: Volulyte is formulated with the synthetic colloid Hydroxyethyl Starch (HES), whereas Gelatin-based products contain a different type of colloid derived from animal protein. Official regulatory and research reports indicate that the choice of fluid is based on the medical professional's assessment of the patient's individual needs.

---

Q: Is Volulyte safe for patients with a history of heart problems?

A: Official information advises caution and special monitoring for patients with pre-existing heart or circulation problems. It is strictly contraindicated (must not be used) in patients with conditions like fluid overload, pulmonary edema (fluid in the lungs), or congestive heart failure.

---

Q: Is Volulyte used in emergency situations or only planned procedures?

A: The medicine is approved for plasma volume replacement following acute blood loss, meaning sudden, significant loss. This primary indication applies to both urgent situations, such as following trauma, and planned major surgical procedures where significant blood loss is anticipated.

---

Q: How is Volulyte eliminated or processed by the body?

A: The active substance, Hydroxyethyl Starch, is continuously broken down by a specific enzyme in the blood called plasma alpha-amylase. The smaller fragments that result from this breakdown are then primarily eliminated from the body via the kidneys (renally excreted).

---

Q: Why is the official guidance for Volulyte so restrictive regarding its use?

A: Official restrictions were put in place by regulatory bodies due to data that showed an increased risk of death and kidney injury when the medicine was used in certain vulnerable populations. Specifically, its use is contraindicated (must not be used) in critically ill patients, including those with sepsis.

---

Q: What kind of studies support the claims in the 'Research Evidence' section?

A: The claims are predominantly supported by Randomized Controlled Trials (RCTs). These are studies that compare Volulyte against other standard intravenous fluids, focusing on outcomes such as short-term hemodynamic stability (stable blood pressure) and potential effects on kidney function and blood clotting.

---

Q: Is Volulyte known to cause electrolyte imbalances?

A: Volulyte is specifically formulated as a balanced electrolyte solution to help minimize the risk of metabolic disturbances, such as changes to the body's pH balance. However, the medicine is contraindicated in patients with certain pre-existing severe electrolyte abnormalities, such as high sodium or high chloride levels.

---

Q: Why would someone need a colloid solution like Volulyte instead of a standard IV drip?

A: Volulyte is indicated for volume replacement only when treatment with alternative solutions, known as crystalloids (standard IV drips), alone is not considered sufficient to restore lost blood volume. The active starch molecules in Volulyte stay in the bloodstream longer than crystalloids, which is why it is used when a more sustained maintenance of intravascular fluid volume is needed in the short term.

---

Q: Is there a maximum amount of Volulyte a patient can receive?

A: Yes, official guidance defines a strict maximum daily dose based on the patient's body weight. Additionally, the regulatory constraints restrict the use of the medicine to only the initial 24-hour phase of volume replacement treatment.

---

Q: Are there concerns about Volulyte's effect on liver function?

A: Yes, official documents specify that the medicine is contraindicated (must not be used) in patients who have severe liver disease. The official documents outline special precautions and monitoring requirements for patients with pre-existing liver problems.

---

Q: Can Volulyte be administered outside of a hospital setting?

A: Regulatory risk minimization measures have restricted the use of this class of medicine to accredited hospitals only. It must be administered by healthcare professionals who are trained in its appropriate and monitored use.

---

Q: Do different countries have different approved uses for Volulyte?

A: The core purpose—plasma volume replacement for acute blood loss—is similar globally. However, specific regulatory language, required monitoring, dosing limits, and restrictions for high-risk populations can and do vary between countries, as set by their respective government agencies.

---

Q: What does 'Volulyte is a medicinal product for restricted use' mean?

A: This term means the product is subject to specific regulatory safety measures due to identified risks. These restrictions limit its use to a tightly controlled patient population (not critically ill) and require it to be administered only in accredited hospitals by trained personnel to mitigate the risks.

---

Q: Are there different brand names for Volulyte in other regions?

A: The active ingredient, hydroxyethyl starch, is sold under several brand names across the globe. Volulyte is a specific trademarked product, but similar hydroxyethyl starch solutions are marketed under different names depending on the country or manufacturer.

---

Q: How does the concentration of the starch component impact the use of Volulyte?

A: Volulyte is a 6% solution. Official documents state that this concentration, along with the specific molecular weight of the starch, is what dictates the initial volume expansion effect and the length of time the substance remains active and effective in the bloodstream.

---

Q: What are the reasons Volulyte might be stopped during treatment?

A: The infusion must be stopped when the appropriate goals for circulating fluid volume are met. It must also be discontinued immediately if the patient develops fluid overload, experiences an allergic reaction, shows the first signs of kidney impairment, or if a blood clotting disorder is detected.

---

Q: Do official documents mention any effects of Volulyte on breathing?

A: Yes. The medicine is contraindicated in patients with pulmonary edema (fluid in the lungs). Furthermore, severe allergic reactions (anaphylactoid reactions) have been reported as a serious risk, and these can include symptoms such as difficulty breathing.

How to Store and Dispose of Volulyte

Official regulatory information outlines specific requirements for the storage and disposal of Volulyte (Hydroxyethyl Starch 130/0.4).

---

Storage and Handling

• Temperature: Volulyte must be stored below 25 C and must not be frozen.
• Packaging: The product should be kept in its overwrap until immediately before use and is for single use only.
• Safety: The solution must be kept out of the sight and reach of children.

---

Disposal Requirements

• Unused Product: Any unused Volulyte solution remaining after treatment must be discarded.
• Environmental Protection: The medicine must not be thrown away via wastewater or ordinary household waste; proper disposal methods should be consulted with a pharmacist.